USFDA halts use of Regeneron, Lilly Covid-19 antibody treatments
New Delhi: The U.S. health regulator revised on Monday the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
The Food and Drug Administration (FDA) said the treatments are currently not cleared for use in any U.S. states or territories, but may be authorized in certain regions if they work against potential new variants.
The agency highlighted other therapies that are expected to be effective against Omicron, including a rival antibody drug from GlaxoSmithKline and Vir Biotechnology as well as recently authorized antiviral pills from Pfizer and Merck & Co.
Last month, the U.S. government had paused the distribution of Regeneron and Lilly's treatments and said the halt would continue until new data emerges on their efficacy against Omicron.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.